伴或不伴同期消融的肝细胞癌经皮影像引导活检的安全性
该回顾性研究纳入2011至2016年连续383例接受影像引导下肝细胞癌活检的成人患者(共398次活检),其中282例(71%)同期行消融治疗。采用标准化间接入路同轴活检技术,不良事件发生率为4.5%(18/398),其中13例为Clavien-Dindo I级或SIR轻微,5例(1.3%)为Clavien-Dindo II-IIIa级或SIR中度;中位随访611天(四分位距211-1104天)内无肿瘤种植事件。结论认为,由受过训练的横断面介入放射科医生在三级肝移植中心操作,该技术伴或不伴同期消融均可安全实施。
要点
- 标准化间接入路同轴活检技术不良事件率4.5%,多数为轻微(Clavien-Dindo I级或SIR轻微)。
- 中位随访611天(四分位距211-1104天)内无肿瘤种植事件发生。
- 基线年龄、性别、肝病病因、肝细胞癌直径及分级与不良事件无关联。
核心结论
- 采用标准化间接入路同轴技术行经皮影像引导肝细胞癌组织取样,伴或不伴同期消融,由三级肝移植中心受过训练的横断面介入放射科医生操作可安全实施。
研究设计与样本
- 经IRB批准、符合HIPAA的回顾性研究,纳入2011至2016年连续成人患者383例,共398次影像引导下肝细胞癌活检(伴或不伴同期消融),采用标准化间接入路同轴活检技术,不良事件分别按Clavien-Dindo并发症分类系统和最新提出的介入放射学会(SIR)不良事件分类系统分级。
诊断标准与关键数值
- 不良事件发生率4.5%(18/398次活检),其中13例为Clavien-Dindo I级或SIR轻微(血肿7例、肝静脉血栓2例、门静脉血栓2例、中等量胸腔积液1例、少量气胸1例);5例(1.3%)为Clavien-Dindo II-IIIa级或SIR中度(需血制品的血肿1例、心律失常1例、需治疗的症状性胸腔积液3例);肿瘤种植定义为后续影像上沿针道出现任何新发病灶,中位随访611天(四分位距211-1104天)内无肿瘤种植事件。
临床应用与阅片要点
- 原文结论认为,由三级肝移植中心受过训练的横断面介入放射科医生操作,采用标准化间接入路同轴技术行经皮影像引导肝细胞癌组织取样,伴或不伴同期消融均可安全实施。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: To determine the prevalence of adverse events after image-guided biopsy of histologically proven hepatocellular carcinomas (HCC) using a standardized, indirect access, coaxial biopsy technique.
METHODS: In this IRB-approved, HIPAA compliant, and retrospective study, we evaluated all consecutive adult patients from 2011 to 2016 who underwent image-guided biopsy of HCC with and without concurrent ablation. Tumor seeding was defined as any new lesion along the needle tract on subsequent imaging. Adverse events were graded using both the Clavien-Dindo Complication Classification system and the most recently proposed Society of Interventional Radiology (SIR) Adverse Event Classification System.
RESULTS: A total of 383 patients underwent 398 biopsies (64 ± 11 years; 112 women, 271 men). Most patients (282; 71%) underwent concurrent ablation. Adverse events occurred after 18 biopsies (4.5%): 13 were Grade I (Clavien-Dindo) or minor (SIR) and included hematoma (7), hepatic vein thrombus (2), portal vein thrombus (2), moderate pleural effusion (1), and small pneumothorax (1). The remaining 5 (1.3%) adverse events were classified as Grade II-IIIa (Clavien-Dindo) or moderate (SIR) and included hematoma requiring blood products (n = 1), arrhythmia (n = 1), and symptomatic pleural effusions requiring treatment (n = 3). Baseline age, sex, cause of liver disease, HCC diameter, and HCC grade were not associated with adverse events. There were no tumor seeding events after a median follow-up of 611 days (interquartile range of 211-1104).
CONCLUSION: Percutaneous image-guided tissue sampling using a standardized, indirect access, coaxial technique can be performed safely with and without concurrent ablation by trained cross-sectional interventional radiologists at a tertiary liver transplant center.
引用
- Tse, Terashima, Shen, et al. Safety of percutaneous, image-guided biopsy of hepatocellular carcinoma with and without concurrent ablation. Abdom Radiol (NY). 2022. PMID: 35396970. doi:10.1007/s00261-022-03494-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。